Introducing Bio V1: A New Era for Decentralized Biotech
Bio V1 is the first major upgrade to Bio, bringing more automation and access to early-stage biotech. Our goal is to reshape how biotech breakthroughs are born, enabling global communities of patients, researchers & crypto investors to create user-owned research networks and back brilliant science from day one.
Imagine a future where supporting biotech research is as easy and global as joining a crypto community.
Bio V1 is the first major upgrade to the Bio Protocol, bringing more automation and access to early-stage biotech. Our goal is to reshape how biotech breakthroughs are born by enabling global communities of patients, researchers and crypto investors to create user-owned research networks (BioDAOs) that back brilliant science from day one.
If we can create value from research, and then accrue and distribute that value across the BIO network, we can build a self-sustaining system for permissionless science.
Breaking Open the Black Box of Life Sciences
Bio V1 is expected to launch in the coming weeks on Solana and Base, introducing a decentralized, multi-chain protocol for funding and developing early-stage biotech.
The core components of Bio V1 – a Launchpad, Liquidity & Incentives Engine, and BioAgents (AI-powered scientific agents) – are all designed to streamline, simplify and gamify biotech funding and development.
Users will be able to lock or stake BIO tokens to perform core functions on the network like vetting new BioDAOs or running BioAgents, with protocol fees recycled back into the ecosystem via liquidity or token burns to fuel growth.
The first BioDAO launches on the protocol will occur in the coming weeks on both Solana and Base, beginning with “curation” by BIO token holders.
It’s time to break open the black box of life sciences with open-source, decentralized technologies. Let’s dive into Bio V1.
In the first phase of Bio V1, BIO holders will curate new BioDAOs that wish to join the network.
Newsletter
Get the latest updates from the Bio ecosystem
New launches, research progress, and ways to get involved across the Biosphere.
How Bio V1 Works
Bio V1 is built around various components, each engineered to make biotech more efficient and market-driven, from launch to funding and liquidity, to incentives and agentic automation.
1. Permissionless Launchpad for Biotech
Bio V1’s launchpad allows new BioDAOs to raise capital through fair, community-based mechanisms. BIO token holders lock their tokens to pledge support for a new BioDAO wishing to join the network. If a BioDAO receives sufficient support, participants who locked their BIO receive the BioDAO’s tokens at a pre-sale valuation. Projects can choose between bonding curves or threshold price auctions to distribute tokens to early backers.
BioDAO tokens represent a stake in that project’s research, while also granting community members a say in how funds and BioDAO revenue are allocated. Anyone can contribute, which means new biotech ventures aren’t bottlenecked by a handful of traditional funders.
The 3 phases of the Bio V1 Launchpad: Curation, Funding & Liquidity.
2. Automated Liquidity Engine
Once a project’s token is initially distributed and research funding is raised, Bio V1 launches a liquidity pool on a decentralized exchange, pairing the new BioDAO token with BIO. This gives participants the freedom to trade and earn liquid stakes right away—rather than waiting months or years for liquidity. Automated liquidity thus brings flexibility and transparency to the biotech funding and scaling process, a key element often lacking in legacy approaches.
3. Milestone-Based Incentives
To ensure accountability, Bio V1 enables milestone-based incentives in the form of BIO tokens. Projects can unlock these rewards by hitting critical R&D milestones, such as completing lab experiments, trials or earning product revenue. This approach aligns everyone’s incentives toward real-world progress, keeping the focus on meaningful scientific outcomes. It also provides standardization in success metrics based on what the community deems most important to the health of the network.
4. BioAgents
A distinctive part of Bio V1 is the introduction of BioAgents - AI-driven scientific researchers that automate tasks for BioDAOs such as data analysis, hypothesis generation, experiment design or IP claims. BioDAOs leverage these “autonomous lab assistants” to speed up and reduce the cost of the scientific process, while reading and writing to a decentralized knowledge graph integrated across BioDAOs. BioAgents also open potential revenue streams, since external organizations can pay fees to access these AI services, creating a self-sustaining feedback loop for the ecosystem.
BioAgents run continuously and becomes part of the BioAgent fleet, taking on given tasks from the BioDAOs.
Users lock or stake BIO tokens to perform core functions on the network, like vetting new BioDAOs or running BioAgents. Protocol fees get recycled back into the ecosystem via liquidity or token burns to fuel growth, while the Bio Protocol Treasury can earn value in the following ways:
6.9% stake in each BioDAO launched via the Launchpad
Launchpad fees from trading, etc.
Percentage stake of IP-Tokens launched via the protocol
Protocol-owned liquidity & paid liquidity management services for BioDAOs
Fees from BioAgents
Protocol fees get recycled back into the ecosystem via liquidity or token burns to fuel growth.
Towards Autonomous Science
Bio V1 unlocks numerous benefits for scientists and backers:
Benefits for Researchers
Rapid Research Funding – BioDAOs can select from a range of bonding curve and auction-based funding mechanisms, optimizing transparency, automation, and community-driven capital allocation.
Automated Liquidity – BIO token pledges enable onchain liquidity provisioning, ensuring sustainable market depth and fee generation for BioDAOs.
Agentic Science – Integrated BioAgents automate core scientific tasks, including data analysis, hypothesis testing, and experimental design and submission to labs, while CoreAgents streamline BioDAO governance and IP management.
Benefits for Backers
Early Access – Pledged BIO secures pre-sale allocations in vetted BioDAOs, offering strategic entry at early-stage valuations.
Community Vetting – Capital deployment is conditional on collective approval, ensuring funds are only allocated to BioDAOs with sufficient community support.
Instant Liquidity – A portion of successfully raised funds is automatically injected into onchain liquidity pools, facilitating immediate, low-slippage trading.
Looking Ahead
Curation Phase Launch – Late March 2025: The Bio Launchpad goes live with the curation module. BIO holders can begin locking their BIO to curate new BioDAOs on Base or Solana.
Funding Phase Launch – Mid April 2025: Fundraising functionality is enabled for the first curated BioDAOs.
Automated Liquidity Phase – Late April 2025: The liquidity provisioning module activates. Successfully funded BioDAOs will seamlessly transition into BIO/BioDAO liquidity pools, making their tokens instantly tradable.
BioAgents Integration – April-May 2025: The first BioAgents come online to assist BioDAOs. AI agents start contributing to research workflows in pilot BioDAOs, demonstrating the power of AI in decentralized science.
This upgrade is more than just a technical milestone; it’s a rallying cry for a more open, distributed approach to biotech.
Anyone can get involved—be it as a citizen scientist, researcher, investor, or someone just passionate about a specific disease or technology. By breaking down traditional biotech barriers and introducing a community-focused, AI-driven framework, Bio V1 has the potential to accelerate life and world-saving discoveries and make them more accessible to all.
Stay tuned as we’ll soon announce the first new BioDAOs up for curation!
